Clinical Trial Update: Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, and activity of ISIS SOD1Rx in familial ALS caused by SOD1 mutations has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• ISIS SOD1Rx

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Familial Amyotrophic Lateral Sclerosis | Phase 1 | Status: COMPLETED